SVChemBiotech - About Us

What we do

We provide chemistry services and are capable of supplying products from gram to multi kilo scale involving complex and multi-step synthesis. We supply to biotech and pharma customers to support their early stage drug discovery and pre-clinical to clinical research activities. We have partnered with WHO GMP and ISO 9001-2008 facilities located in India manufacturing APIs and intermediates. We conduct process R&D, technology transfer and manufacture of key starting materials, advanced intermediates for APIs going to clinical studies.

We also conduct process development and manufacture of advanced intermediates for Generic APIs in partnership with Indian facilities. In addition we develop and synthesize stable deuterium labelled drug standards and metabolites and supply to leading pharmaceutical companies all over the world. We also develop and manufacture semiochemicals for crop protection, specialty chemicals for photography applications.

Custom Synthesis

We perform synthesis of intermediate, reference or lead compounds
We can also exercise an existing synthesis or design a new synthesis when there is no developed chemical plan

Process Research

Can undertake projects for process research, scale up and technology commercialization for preclinical and clinical drug candidates, APIs, pharmaceutical intermediates and specialty chemicals in our cGMP compliant facilities

Drug-like and Lead-like Compounds for Screening

We provide a diverse library of small molecule compounds for screening against your targets
We can create a synthesis plan for your hit compounds
We can design and synthesize a custom library for lead identification and lead optimization

Why SVChemBiotech?

Our experience, combined with state-of- the-art laboratories and manufacturing facilities lets us become an ideal partner for the pharmaceutical and drug discovery industry. We work efficiently and offer a competitive price while maintaining full confidentiality regarding clients' intellectual property.

News

2023

In November 2023, we hired two R&D Trainees (pharmaceutical R&D and manufacturing) in SV ChembioTech in partnership with Technology Alberta through the 'First Jobs, Work Integrated Learning (WIL)' program.

FIRST Jobs (First Industrial Research, Science, or Technology) is a Job placement partnership program between Alberta companies and Technology Alberta, with support from the Government of Alberta and the Government of Canada.
2021

Developed efficient, cost-effective syntheses and scale up of lead drug candidates and delivered to large pharma customer, AstraZeneca, EMD Serono, USA.

Developed an efficient scale up synthesis of L-2-Aminooxy-3-Phenylpropionic Acid and delivered to our customer University of Florida.

Developed an efficient scale up synthesis of a chiral auxiliary compound and delivered to large pharma customer, Eli Lilly, USA.

SV Chem received "MITACS Accelerate Industrial Joint Postdoc" to support research, technology commercialization of complex pheromone products for supplying to a prestigious customer in California. For this project, we have signed a research collaboration with a chemistry professor from University of Alberta, Edmonton.
2020

We received Industry R&D Associates Program Grant from Alberta Innovates, Canada to develop advanced chlorination technology for optimizing existing manufacturing process for one of our commercial products, CRS pheromone.
2019

Awarded with NRC Industrial Research Assistance Program (NRC-IRAP), by National Research Council Canada for developing an efficient, cost-effective “Oxidation technology” to use in the manufacturing of an API intermediate. The API is used for treating Parkinson’s disease, hyperprolactinemic disorders.

Awarded with NSERC Engage / Alberta Innovates CASBE Grant to conduct research on "High-throughput microfluidic technology" for developing small 3D tissues to identify new therapeutic pathways for cancer therapy in collaboration with University of Calgary.
2018

Developed novel synthesis and delivered complex library compounds to EMD Serono.

Developed synthesis of a complex chiral beta-amino acid, delivered to Merck KGaA.

Developed and delivered complex med-chem screening compounds to Biogen.

Developed and delivered novel synthetic routes for various deuterium drug standards and metabolites to clients.

Developed a novel route for synthesis of a green house pheromone(SMID: ascr#18, active on organism C. elegans) and delivered to a customer in California, USA for field trials.

Participated in CPhi Worldwide 2018 held in Madrid, attended an introductory session organized by the Canadian Ambassador to Spain

Our President has been invited to speak in the 102nd Canadian Chemistry Conference and Exhibition in June 2019 in Quebec, Canada, organized by the Canadian Society for Chemistry.
2017

Participated in Bio International Convention 2017 held in San Diego, USA.

Developed an efficient synthesis for a key intermediate of a preclinical API and delivered to a customer in USA. We received appreciation from the customer for successful execution of synthesis and timely delivery. Customer placed with us another order for a 2 nd campaign of the same intermediate.

Developed a manufacturing process and delivered in multiple kilos of California red scale Pheromone (CRS pheromone) to a customer in Canada. CRS pheromone is used for control of California red scale pest on citrus trees.
2016

Received NSERC Engage Plus award from NSERC Canada to conduct research on “Efficient Chemical Synthesis of Deuterated Pharmaceutical Standards and Metabolites” in collaboration with University of Alberta.

Initiated and completed a multi-kilo project for a US customer for developing and manufacturing of an advanced intermediate for a clinical API used in treating HIV infection and AIDS.
2015

Participated in a collaborative research project "Copper-Mediated Carbon-Carbon Bond Formation Reactions with Heterocyclic Compounds" with University of Alberta supported by “NSERC Engage” from Natural Sciences and Engineering Research Council of Canada.
2014

Developed a novel manufacturing process of an advanced intermediate for a clinical API used in treating Friedreich’s ataxia. Supplied multi kilos quantities to a customer in USA.

Developed a multi-step novel synthesis for an advanced intermediate of a generic API used for treating Parkinson's disease. Supplied in kilo quantities to a customer in Brazil.
2013-2016

Developed novel synthetic routes and delivered several complex “New Chemical Entities” to Thermofisher Scientific's customer Sanofi for drug discovery programs.
2012-2013

Entered into a collaboration with Indian manufacturing facility for research and developing a new technology for an advanced intermediate for a pre-clinical drug used in treating “Friedreich’s ataxia”, rare inherited disease that causes nervous system damage.
2011-2012

Participated in a collaboration with Albany Molecular Research (USA) to develop and deliver various complex “New Chemical Entities” for pre-clinical research. Received an appreciation from the customer.